The ongoing legal case between The New York Times and the European Commission regarding the lack of transparency in COVID-19 vaccine contracts has reached the hearing phase in Luxembourg. The case arose from the efforts of Matina Stevis-Gridneff, the former Brussels bureau chief of The New York Times, to access text messages exchanged between European Commission President Ursula von der Leyen and Pfizer CEO Albert Bourla. The newspaper initially reported in April 2021 that such messages existed and were related to vaccine contracts, but faced difficulties when requesting their disclosure. Despite multiple unsuccessful attempts to obtain the messages, the matter escalated to the European Court of Justice (ECJ) in January 2023.
At the heart of the case is the principle of transparency surrounding public access to documents within the European Union. The New York Times argues that the EU’s 2001 regulation on public access includes text messages as “documents” that should be archived and made available. The regulation broadly defines a document as any content that pertains to the policies and decisions of the EU. The Times contends that the Commission has failed to adequately document and register these critical messages, while the Commission’s legal team argues that text messages are ephemeral and do not typically meet the formal criteria for inclusion in the institution’s document management systems.
The European Commission maintains that the text messages between von der Leyen and Bourla were not archived because they were informal conversations that did not contain substantial information warranting further action. During his interview, Bourla indicated that the texts were private exchanges, reinforcing the Commission’s stance that they should not be classified as official documents. Despite what the Commission describes as a “renewed” search yielding no results, The New York Times remains adamant that the failure to disclose these messages violates the principles of transparency and accountability.
The legal battle is set against a broader backdrop of scrutiny over the EU’s COVID-19 vaccine procurement processes. The Pfizer-BioNTech vaccine was among the first to receive EU approval, with substantial contracts being negotiated for millions of doses during the early pandemic. However, subsequent transparency concerns emerged, including a recent ECJ ruling that annulled parts of Commission decisions to redact key areas of vaccine contracts, thereby emphasizing the need for public access to such agreements. These transparency issues have led to rising public distrust and allegations about the procurement process.
Adding to the controversy, the European Public Prosecutor’s Office (EPPO) has been investigating the EU’s vaccine procurement processes since October 2022, although it has yet to reach any conclusions. Meanwhile, a Belgian tribunal is set to determine jurisdiction over potential misconduct allegations concerning these procurement practices. In this legal landscape, the hearing in Luxembourg is crucial, but observers do not expect a swift resolution, as judicial processes in such cases typically extend over several months.
Ultimately, this case could set critical precedents regarding public access to EU documents and underline the continuous struggle for transparency in government dealings. As the challenges of the pandemic continue to resound, transparency in vaccine procurement and decision-making processes remains a vital issue for citizens and the press alike. The outcome of this legal confrontation may reshape how future documents are managed and disclosed within the EU, potentially leading to increased accountability and trust in public health initiatives. The case highlights the ongoing tension between privacy, transparency, and accountability in the interplay between governmental institutions and private entities like pharmaceutical companies.
